Proliferation-Guided Risk Stratification in HER2-Low versus HER2-Positive Hormone Receptor-Positive Breast Cancer: A Multicenter Retrospective Analysis.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
3 patients, disease-free survival (DFS) was significantly longer in the HER2-low subgroup (median: 86 vs.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Dual stratification by HER2 and Ki67 status may improve risk assessment and help identify high-risk subgroups who could benefit from treatment approaches beyond endocrine therapy alone. These findings warrant confirmation in prospective studies.
[INTRODUCTION] HER2-low breast cancer is a newly characterized subgroup with unclear prognostic implications.
- 표본수 (n) 156
- p-value p < 0.001
- 95% CI 1.564-2.048
- HR 1.664
APA
Kitapli S, Tanrıverdi Ö, et al. (2026). Proliferation-Guided Risk Stratification in HER2-Low versus HER2-Positive Hormone Receptor-Positive Breast Cancer: A Multicenter Retrospective Analysis.. Oncology research and treatment, 1-16. https://doi.org/10.1159/000550484
MLA
Kitapli S, et al.. "Proliferation-Guided Risk Stratification in HER2-Low versus HER2-Positive Hormone Receptor-Positive Breast Cancer: A Multicenter Retrospective Analysis.." Oncology research and treatment, 2026, pp. 1-16.
PMID
41528926 ↗
Abstract 한글 요약
[INTRODUCTION] HER2-low breast cancer is a newly characterized subgroup with unclear prognostic implications. This study investigates the prognostic role of Ki67 in hormone receptor-positive (HR+) HER2-low and HER2-positive breast cancer.
[METHODS] We retrospectively analyzed 224 HR+ breast cancer patients from four tertiary centers (96 HER2-low, 128 HER2-positive). Patients were stratified into stages 1-3 (n = 156) and stage 4 (n = 68). Survival outcomes were assessed according to HER2 and Ki67 status using Kaplan-Meier analysis and Cox regression.
[RESULTS] HER2-low patients were older (≥65 years: 65% vs. 28%, p < 0.001). In stage 1-3 patients, disease-free survival (DFS) was significantly longer in the HER2-low subgroup (median: 86 vs. 59 months; p < 0.001) and in those with Ki67 < 20% (median: 74 vs. 34 months; p < 0.001). Multivariable analysis confirmed high Ki67 (HR: 1.664; 95% CI: 1.564-2.048; p < 0.001), hormone receptor negativity (HR: 1.967; 95% CI: 1.614-2.433; p = 0.020), larger tumor size, and axillary nodal involvement as independent predictors of poor DFS. Among stage 4 patients, overall survival (OS) did not differ significantly by HER2 status (34 vs. 28 months; p = 0.427) but was significantly shorter in those with Ki67 ≥ 20% (18 vs. 29 months; p < 0.001). In multivariable analysis, high Ki67 (HR: 2.174; 95% CI: 1.994-2.256; p < 0.001), hormone receptor negativity (HR: 1.649; 95% CI: 1.184-2.143; p < 0.001), and presence of brain metastasis (HR: 1.564; 95% CI: 1.379-1.994; p < 0.001) were independent predictors of poor OS.
[CONCLUSION] Ki67 appears to be an important prognostic biomarker in HR+ breast cancer across both HER2-low and HER2-positive subgroups. Dual stratification by HER2 and Ki67 status may improve risk assessment and help identify high-risk subgroups who could benefit from treatment approaches beyond endocrine therapy alone. These findings warrant confirmation in prospective studies.
[METHODS] We retrospectively analyzed 224 HR+ breast cancer patients from four tertiary centers (96 HER2-low, 128 HER2-positive). Patients were stratified into stages 1-3 (n = 156) and stage 4 (n = 68). Survival outcomes were assessed according to HER2 and Ki67 status using Kaplan-Meier analysis and Cox regression.
[RESULTS] HER2-low patients were older (≥65 years: 65% vs. 28%, p < 0.001). In stage 1-3 patients, disease-free survival (DFS) was significantly longer in the HER2-low subgroup (median: 86 vs. 59 months; p < 0.001) and in those with Ki67 < 20% (median: 74 vs. 34 months; p < 0.001). Multivariable analysis confirmed high Ki67 (HR: 1.664; 95% CI: 1.564-2.048; p < 0.001), hormone receptor negativity (HR: 1.967; 95% CI: 1.614-2.433; p = 0.020), larger tumor size, and axillary nodal involvement as independent predictors of poor DFS. Among stage 4 patients, overall survival (OS) did not differ significantly by HER2 status (34 vs. 28 months; p = 0.427) but was significantly shorter in those with Ki67 ≥ 20% (18 vs. 29 months; p < 0.001). In multivariable analysis, high Ki67 (HR: 2.174; 95% CI: 1.994-2.256; p < 0.001), hormone receptor negativity (HR: 1.649; 95% CI: 1.184-2.143; p < 0.001), and presence of brain metastasis (HR: 1.564; 95% CI: 1.379-1.994; p < 0.001) were independent predictors of poor OS.
[CONCLUSION] Ki67 appears to be an important prognostic biomarker in HR+ breast cancer across both HER2-low and HER2-positive subgroups. Dual stratification by HER2 and Ki67 status may improve risk assessment and help identify high-risk subgroups who could benefit from treatment approaches beyond endocrine therapy alone. These findings warrant confirmation in prospective studies.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Early local immune activation following intra-operative radiotherapy in human breast tissue.
- Overall survival and prognostic factors in young women with breast cancer: a retrospective cohort study from Southern Thailand.
- Age at First Pregnancy, Adult Weight Gain and Postmenopausal Breast Cancer Risk: The PROCAS Study (United Kingdom).
- Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates.
- Structural determinants of glycosaminoglycan oligosaccharides as LL-37 inhibitors in breast cancer.
- Artificial intelligence and breast cancer screening in Serbia: a dual-perspective qualitative study among radiologists and screening-aged women.